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Abstract 
Background: Translating genomic technologies into healthcare applications for the malaria parasite Plasmodium fal-
ciparum has been limited by the technical and logistical difficulties of obtaining high quality clinical samples from the 
field. Sampling by dried blood spot (DBS) finger‑pricks can be performed safely and efficiently with minimal resource 
and storage requirements compared with venous blood (VB). Here, the use of selective whole genome amplification 
(sWGA) to sequence the P. falciparum genome from clinical DBS samples was evaluated, and the results compared 
with current methods that use leucodepleted VB.
Methods: Parasite DNA with high (>95%) human DNA contamination was selectively amplified by Phi29 polymerase 
using short oligonucleotide probes of 8–12 mers as primers. These primers were selected on the basis of their differ‑
ential frequency of binding the desired (P. falciparum DNA) and contaminating (human) genomes.
Results: Using sWGA method, clinical samples from 156 malaria patients, including 120 paired samples for head‑to‑
head comparison of DBS and leucodepleted VB were sequenced. Greater than 18‑fold enrichment of P. falciparum 
DNA was achieved from DBS extracts. The parasitaemia threshold to achieve >5× coverage for 50% of the genome 
was 0.03% (40 parasites per 200 white blood cells). Over 99% SNP concordance between VB and DBS samples was 
achieved after excluding missing calls.
Conclusion: The sWGA methods described here provide a reliable and scalable way of generating P. falciparum 
genome sequence data from DBS samples. The current data indicate that it will be possible to get good quality 
sequence on most if not all drug resistance loci from the majority of symptomatic malaria patients. This technique 
overcomes a major limiting factor in P. falciparum genome sequencing from field samples, and paves the way for 
large‑scale epidemiological applications.
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Background
The last decade has seen rapid advances in whole genome 
sequencing technologies helping to track disease out-
breaks and the spread of drug resistance genes [1]. 
Clinical and public health applications for Plasmodium 
falciparum sequencing rely on obtaining sequenceable 
material from samples collected in the field, often in 
resource-limited conditions. To date, the practical dif-
ficulties in sample collection, storage and transporta-
tion impose significant barriers to the use of genomic 
approaches for malaria surveillance.
The most practical and convenient method for sam-
pling clinical malaria parasites is through small blood 
volumes obtained from capillary blood using finger or 
heel-pricks [2, 3]. These small blood samples—about 
50 µl in volume—are blotted on filter papers for efficient 
transportation and storage without requiring refrigera-
tion; this is especially applicable to resource-deprived 
regions where the disease is endemic. Despite the con-
venience and ease of sampling, DNA extracted from 
dried blood spot (DBS) filter papers often has low para-
site DNA yield and an overwhelming host DNA contami-
nation, which poses serious limitations in downstream 
genetic analyses [4]. These technical bottlenecks have 
prevented analysis of large numbers of pathogen samples 
collected by DBS at whole genome resolution, including 
archived clinical specimens, using current high through-
put sequencing technologies.
Currently, whole blood from malaria patients used for 
P. falciparum sequencing is obtained through venous 
blood (VB) draws. This requires skilled phlebotomists or 
clinicians with appropriate training. Once collected, VB 
samples are processed by filtering out leucocytes using 
cellulose columns [5] and require refrigerated storage 
followed by centrifugation and blood pellet freezing or 
DNA extraction. These requirements limit the scope for 
sample collection in remote regions where healthcare 
infrastructure is already under strain. The cellulose filtra-
tion process, although very effective in parasite enrich-
ment, requires large volumes of blood (>2 ml) [6]. Such 
volumes can be difficult to obtain, especially from young 
children, who may already be anaemic as a result of P. fal-
ciparum infection [7] and who bear the heaviest disease 
burden globally.
To overcome the challenges of low sample quality and 
quantity, and to allow timely genetic analysis of clinical 
samples collected directly from patients without culture 
adaptation, an approach was used that selectively ampli-
fies parasite DNA from low blood volume clinical sam-
ples. The selective whole genome amplification (sWGA) 
strategy, originally described by Leichty and Brisson 
[8], uses computationally selected short oligonucleotide 
probes of 8–12  mers as primers that preferentially bind 
to the target genome, and this approach has been suc-
cessfully applied to Laverania parasites, including P. fal-
ciparum [9, 10]. The purpose of the present study was to 
undertake a detailed evaluation of sWGA approaches for 




In order to design probes that preferentially bind to the 
P. falciparum genome, a published PERL script [8] was 
used to select up to 100 (8–12 mer) primers with a pre-
dicted specified melting temperature (≤30  °C). The fre-
quency of these primer sequences in the desired (D) 
Plasmodium falciparum 3D7 genome were compared to 
the contaminating (C) human genome (Fig.  1a). Top 50 
primers with the highest desired/contaminating (D/C) 
ratios were selected for further analysis. From these 50, 
primers with more than three complementary nucleo-
tides at 3′ and 5′ ends were removed to prevent forma-
tion of hairpin structures. To prevent primer–primer 
dimerization, primer pairs with more than three com-
plementary nucleotides at their ends were also removed. 
A final 28 primers that passed the above quality control 
were ordered from Integrated DNA Technologies (Cor-
alville, IA) as standard desalting purification with a single 
modification of phosphorothioate bond between the last 
two 3′ nucleotides to prevent primer degradation by the 
Phi29 polymerase exonuclease activity. Individual prim-
ers were reconstituted in Tris HCl (pH 8.0) buffer and 
pooled into three sets (probes) following the D/C rank-
ing described above: the first set consisted of the first 
10 primers (Probe_10), the second set consisted of the 
first 20 primers (Probe_20), and the third set consisted 
of all 28 primers (Probe_28). Each set was evaluated to 
determine which should be taken forward for further 
assessment.
Mock samples to test the efficacy of sWGA
To test whether selected primers would successfully 
amplify the parasite genome, mock clinical samples 
were prepared by mixing culture-infected red blood cells 
(infected with P. falciparum strain 3D7) with uninfected 
human whole blood to obtain a simulated parasitaemia 
ranging from 0.0001 to 1%. P. falciparum strain 3D7 par-
asites for the mock samples were cultured in human O+ 
erythrocytes with heat-inactivated 10% pooled human 
serum, as described in [11]. All parasitaemia calculations 
were based on the estimation of approximately 4 million 
red blood cells per microlitre of whole blood. DNA was 
extracted from the samples (N = 8) without leucodeple-
tion. In addition, 6 other mock DNA samples were manu-
ally reconstituted by mixing P. falciparum genomic DNA 
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with host (human) genomic DNA to obtain parasite/host 
DNA mixtures of the ratio 1: 24 (4% parasite and 96% 
human DNA) that were used to investigate genome cov-
erage following sWGA.
Whole genomes from dried blood spots
To test the efficacy of sWGA in generating reliable 
genomic data from DBS, WGS datasets obtained from 
standard leucodepleted-genomic DNA (gDNA) were 
compared with sWGA-DBS samples. The gDNA samples 
were derived from two to three ml of venous blood which 
were then processed by CF-11 or MN filtration to remove 
leucocytes [5, 6] prior to DNA extraction. On the other 
hand, the DBS samples were collected by spotting (on fil-
ter paper) 50 μl of whole blood obtained by finger prick-
ing. In total, samples from 156 patients that were positive 
for P. falciparum clinical malaria based on rapid diag-
nostic test (RDT) with CareStart™ Malaria kit (Access 
Bio Inc, USA) were analysed. Eighty-four DBS were col-
lected from the Kassena-Nankana Districts of Upper 
East Ghana, of which 48 had matching VB pairs; and 72 
DBS were collected from Noguchi Memorial Hospital in 
Accra, Ghana, all of which had matching VB samples.
DNA extraction and quantification
Two to three ml of VB samples (mock blood or field) were 
used to extract DNA, using QiAamp DNA blood midi kit 
(Qiagen) following the kit manufacturer’s instructions. 
For DBS, DNA was extracted using QIAamp DNA Inves-
tigator Kit (Qiagen, Valencia, California, United States). 
Approximately 1.5 cm (0.6 in) diameter DBS circles from 
each filter paper were cut out into small pieces of 3 mm 
diameter using a single-hole paper punch. Punched 
pieces from each sample were placed into 2  ml micro-
centrifuge tubes from which DNA was extracted follow-
ing the manufacturer’s instructions except for the reagent 
volumes and incubation times, which were doubled to 
accommodate the increased amount of DBS used per 
sample. An average of 116  ng (standard deviation, SD, 
116.7) of DNA was obtained from the DBS extracts out 
of which at least 5  ng was used as template for sWGA 
amplification reaction.
Selective whole genome amplification (sWGA)
The sWGA reaction was performed in 0.2 ml PCR-tubes 
or plates. The reaction (50 µl total volume) containing at 
least 5 ng of template DNA, 1× BSA (New England Bio-
labs), 1  mM dNTPs (New England Biolabs), 2.5  µM of 
each amplification primer, 1× Phi29 reaction buffer (New 
England Biolabs), and 30 units of Phi29 polymerase (New 
England Biolabs), was placed in a PCR machine (MJ ther-
mal Cycler, Bio-Rad) programmed to run a “stepdown” 
protocol consisting of 35 °C for 5 min, 34 °C for 10 min, 
33 °C for 15 min, 32 °C for 20 min, 31 °C for 30 min, 30 °C 
for 16  h then heating at 65  °C for 15  min to inactivate 
the enzymes prior to cooling to 4  °C. Once the product 
Fig. 1 Primer selection analysis. a The frequency of each primer as ranked by the frequency of occurrence. The y‑axis represents the calculated ratio 
of the frequency in the parasite (desired) genome against frequency in the human (contaminating) genome. The x‑axis shows the order of ranking 
by the frequency of occurrence ratio. b DNA yield obtained following the selective whole genome amplification with different pools of probe sets. 
Probe_10 represent a pool of the first top 10 ranking primers. Probe_20 is a cumulative mixture consisting of all the Probe_10 primers plus the 
next 10 probes in that order. Probe_28 is a cumulative mixture of all the first 28 primers (Probe_10, Probe_20 and the next 8 probes in the order of 
frequency ranking)
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was amplified, it was quantified using Qubit® dsDNA 
high sensitivity (Thermo Fisher Scientific) to determine 
whether there was enough material for sequencing—
minimum required is 500 ng of product. Standard whole 
genome amplified (WGA) products of the test samples 
were also sequenced as control to determine the extent of 
enrichment [12].
Library preparation of amplified samples and short read 
high throughput sequencing
sWGA products (≥500 ng total DNA) were cleaned using 
Agencourt Ampure XP beads (Beckman Coulter) fol-
lowing manufacturer’s instructions. Briefly, 1.8 volumes 
of beads per 1 volume of sample were mixed and incu-
bated for 5  min at room temperature. After incubation, 
the tube containing bead/DNA mixture was placed on a 
magnetic rack to capture the DNA-bound beads while 
the unbound solution was discarded. Beads were washed 
twice with 200  µl of 80% ethanol and the bound DNA 
eluted with 60  µl of EB buffer. Cleaned amplified DNA 
products (~05–1 µg DNA) were used to prepare a PCR-
free Illumina library using the NEBNext DNA sample 
preparation kit (New England Biolabs) for high through-
put sequencing. DNA libraries were sequenced at the 
Wellcome Trust Sanger Institute using Illumina HiSeq 
2500 instruments and Illumina V.3 chemistry. Paired-
end sequencing was performed with 100-base reads and 
an 8-base index read. 12-multiplex sample libraries were 
loaded to target at least 20 million reads per sample.
Data analysis
Sequence data obtained from each sample was subjected 
to standard Illumina QC procedures and 20 million reads 
per sample was subjected to detailed analysis for enrich-
ment, quality, content, and coverage. Each dataset was 
analysed independently by mapping sequence reads 
to the 3D7 reference genome using BWA [13]. SAM-
tools [14] was used to generate coverage statistics from 
the BWA mapping output. For enrichment analysis, the 
number of reads mapping to either host, or P. falcipa-
rum reference sequences was counted. For genotype 
and concordance analysis, variant calls were generated 
using SAMtools mpileup (V0.1.1.19; with the follow-
ing parameters: -DSV -C50 -m2 -F0.0005 -d 10,000 -gu) 
and bcftools (V0.1.17; with the following parameters: -p 
0.99 -vcgN). A list of 1,241,840 (1.2 million) high-quality 
single-nucleotide polymorphism (SNP) positions, which 
were not filtered by gene class or region, but on indi-
vidual properties of SNPs (such as uniqueness of the sur-
rounding region and within an exon) [15, 16] was used. 
In silico genotyping of both the DBS (sWGA) and VB 
(leucodepleted and unamplified) samples was performed 
using mpileup to count alleles present in at least five 
reads (alleles with less than five reads were discarded). 
Although P. falciparum is haploid, it is common to find 
heterozygous calls due to the presence of multiple clonal 
infections in the same host. In order to genotype hete-
rozygous sites, the 5/2 rule was applied, which requires at 
least two reads in both reference and alternative alleles, 
and the sum of both has to be higher than five reads [15]. 
SNP call concordance analysis between matching DBS 
and VB samples was performed on sequenced data tar-
geting SNPS present in the core genome as well as key 
malaria drug resistance genes, such as crt (K76T involved 
in chloroquine resistance) [17], dhfr (N51I, involved in 
pyrimethamine resistance) [18], dhps (A581G, involved 
in sulfadoxine resistance) [19], mdr1 (N86Y, involved in 
multiple drugs including mefloquine) [20], and kelch13 
(C580Y, involved in artemisinin resistance) [1].
Results
sWGA primer selection and amplification yield
Selected 28 primers were analysed individually (Fig.  1a) 
to determine their expected binding sites and distribu-
tion pattern across the P. falciparum genome. Each 1 or 
2  kb block had at least one primer binding (Additional 
file 1: Figure S1). These 28 primers were pooled into three 
different sets (probes): Probe_10 (consisting of the first 
10 primers), Probe_20 (consisting of the first 20 primers), 
and Probe_28 (a pool of all the 28 primers). In separate 
reactions, the three probes were used to amplify 5  ng 
of simulated mock samples (a mix of 3D7-infected red 
blood cells with uninfected human whole blood; N = 8) 
to determine which set gives optimal genome amplifica-
tion and coverage. The amplified products were cleaned 
and the DNA quantified using Quant-iT™ PicoGreen® 
dsDNA assay kit (Invitrogen) to determine the yield for 
each primer pool (Fig. 1b). Different yields were observed 
between the three primer pools: Probe_10 produced 
the highest average yield (2.5  ±  0.87  µg) followed by 
Probe_20 (1.85 ±  0.81  µg) and Probe_28 (1.2 ±  1.0  µg) 
(Fig.  1b). Whole genome sequencing of the amplified 
products were used to compared the quality of genome 
coverage (number of bases with at least 5x coverage) 
by each set (pool) and no significant difference was 
found (Spearman’s correlation: Probe_10 and Probe_20, 
R2 = 0.97, p < 0.001; Probe_10 and Probe_28, R2 = 0.96, 
p < 0.001; Probe_20 and Probe_28, R2 = 0.97, p < 0.001). 
Probe_10 (Additional file 1: Table S2) was therefore cho-
sen for all subsequent sWGA reactions based on amplifi-
cation yield and cost.
Coverage profile of sWGA samples
To perform a more in-depth analysis on Probe_10, a 
mock sample containing a mixture of human (96%) and 
P. falciparum (4%) DNA was amplified and sequenced, 
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as described in Methods. Using the Illumina short read 
sequence data obtained, the primer binding positions as 
well as the short-read sequence alignments was plotted 
against the reference genome using Circos software [21] 
for data visualization. Figure 2 shows the probe binding 
sites (middle circle) as well as the sequence reads cov-
erage profile (outermost circle) on all 14 chromosomes 
(inner circle) of the P. falciparum genome. Probe_10 suc-
cessfully amplifies the majority of the parasite genome, 
but the variable subtelomeres are not adequately cov-
ered (Fig.  2; Additional file  1: Figure S1). However, the 
coverage profile is uneven and does not correlate prop-
erly with the primer binding sites (Pearson’s correlation 
R2 = −0.007, p = 0.3).
Previous analysis [15] revealed accessible and inac-
cessible regions in the P. falciparum genome. Inacces-
sible regions, mainly the telomeres, centromeres and 
sub-telomeres, are comprised of hypervariable and/or 
highly repetitive sequences that are difficult to assem-
ble or map. The remaining parts (core genome) consist 
of mainly the coding sequences of relatively balanced-
base composition, and are generally accessible in most 
genome analysis. In order to test whether sequences 
generated from sWGA samples would successfully cover 
the core genome, coverage profile of P. falciparum strain 
3D7 samples sequenced as gDNA (3 samples without 
amplification), WGA DNA (3 samples amplified using 
optimized whole amplification method [12]) or sWGA (3 
Fig. 2 Circos plot analysis of Probe_10 primer pool and P. falciparum genome coverage. The three rings represent, from innermost to outermost, the 
14 P. falciparum chromosomes and position in kb, the total number of primers binding in 1 kb windows (red lines), and the average read depth in 
1 kb windows (blue lines). The figure was generated using the Circos software [21]
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samples consisting of a mixture of 4% parasite and 96% 
human DNA, amplified using selective whole genome 
amplification method) was plotted. Figure  3 shows the 
coverage profile of the samples on chromosome 1, high-
lighting regions corresponding to the core genome. 
Unamplified DNA (gDNA) provided the most even and 
uniform coverage across the entire genome. Both WGA 
and sWGA samples produced relatively spiky and uneven 
coverage, with the sWGA producing higher coverage 
depths of uneven distribution.
sWGA enriches for Plasmodium falciparum sequence reads
The sequence data was analysed by comparing datasets 
from standard whole genome amplified (WGA) sam-
ples against their selectively amplified (sWGA) counter-
parts to determine the level of enrichment. An average of 
73.2% (sd 4.4; N = 5) of the reads in the sWGA-treated 
samples mapped to P. falciparum. More than 18-fold 
enrichment of parasite DNA was achieved, depend-
ing on the extent of host contamination in the original 
sample (Table 1; Fig. 4). In contrast, data obtained from 
DBS extracts and amplified by standard WGA (no selec-
tive amplification) had <1% of reads mapping to P. falci-
parum and the rest (>99%) mapping to the host genome 
(Table 1; Fig. 4), demonstrating the efficacy of sWGA in 
selective amplification of parasite DNA.
Parasitaemia and genome coverage threshold in mock 
samples
To investigate the sensitivity of the sWGA application, 
genome coverage threshold by sequence data generated 
from samples with different levels of parasitaemia was 
analysed. In  vitro infected red blood cells were mixed 
with human whole blood to simulate different levels of 
Fig. 3 Core genome coverage profile. Coverage depth of chromosome 1 by leucodepleted and unamplified (VB), whole genome amplified (WGA) 
and selective whole genome amplified (sWGA) DNA of P. falciparum strain 3D7. Black horizontal line shows positions corresponding to the core 
genome and red vertical line shows the centromere
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clinical parasitaemia ranging from 1.0 to 0.0001%. For 
samples with a parasitaemia of ≥0.005% [~6.25 para-
sites per 200 white blood cells (WBC)], ≥70% of the core 
nuclear 3D7 genome was covered at depth of ≥5× reads. 
However, the coverage dropped sharply for samples with 
parasitaemia below 0.005% (Fig. 5a; see Additional file 1: 
Figure S2 for detailed coverage distribution). The same 
dataset was used to analyse coverage of known impor-
tant drug resistant loci in the genome [22]. As shown in 
Fig.  5b, a similar coverage profile was observed where 
all the 7 specified drug resistant loci were covered 100% 
at depths of ≥5× reads for samples with parasitaemia 
≥0.005%.
sWGA allows whole genome sequencing directly 
from clinical dried blood spots
Having established sWGA efficacy in mock blood sam-
ples, DBS field isolates collected from two sites in Ghana, 
with a parasitaemia ranging from 0.001 to 8.9% (1.25–
11,125 parasites per 200 WBC or 40–356,000 parasites 
per µl of blood) were used to test the method. DNA was 
extracted from 205 DBS samples (average yield 116  ng, 
SD 116.7), which were subsequently subjected to sWGA 
(average yield 1399  ng, SD 502). From those, 156 (76%) 
passed the threshold of 500  ng for library preparation 
and were, therefore, whole genome sequenced.
A total of 156 DBS samples were analysed, excluding 
those with <50% of the core genome covered at 5× reads 
or less (N =  25). On average only 2.3% (SD 2.3) of the 
core genome of the 131 DBS samples was not covered at 
all (Fig. 6a), whereas 85% (SD 13) of the core genome was 
covered at 5× or more (Fig. 6b). The median coverage of 
the core genome was 29× (Fig. 6c).
As expected, samples with higher parasitaemia (above 
0.1%) produced sequence data with better coverage 
at depths of ≥5×, whereas samples with parasitaemia 
lower than 0.03% had many positions covered at depths 
<5× (Fig. 7, F(1,150) = 135.5, p < 0.001). In this dataset all 
samples with parasitaemia lower than 0.03% (N  =  25) 
had more than 50% of the genome covered at 5× or less. 
There was one exception; a sample with 0.001% parasi-
taemia had 51.4% of the core genome covered at 5×. The 
samples with low parasitaemia had a much larger propor-
tion of missing bases in the core genome (Fig. 7). Cover-
age of genes that are either responsible for, or associated 
with, anti-malarial drug resistance (Additional file  1: 
Figure S3) were analysed, and a general tendency of bet-
ter coverage in samples of higher parasitaemia (>0.02%) 
was observed, while those with parasitaemia lower than 
0.01% showed poor coverage across the genes.
Table 1 sWGA enrichment analysis
Mock and field samples were amplified by either WGA or sWGA before sequencing. Proportions of reads mapping to either human or P. falciparum genomes were 
used to determine the level of parasite DNA enrichment by sWGA treatment. 3D7 represent mock samples prepared by mixing P. falciparum and human genomic DNA 
in the ratio of 1:24 (4% parasite and 96% human). Field represent clinical genomic DNA samples extracted from dried blood spot filter papers
Reads mapping to:
Sample P. falciparum (%) Human (%) Others (%) Fold 
enrich-
ment
WGA_3D7_1 3.30 96.20 0.50 N/A
WGA_field_1 2.90 95.83 1.27 N/A
sWGA_3D7_1 79.74 3.33 16.94 19.93
sWGA_3D7_2 74.64 4.82 20.54 18.66
sWGA_Field_1 73.50 4.45 22.04 N/A
sWGA_Field_2 69.26 4.81 25.93 N/A
sWGA_Field_3 68.84 5.51 25.61 N/A
Fig. 4 Selective whole genome amplification (sWGA) enrichment. 
Simulated clinical samples comprising 96% human DNA and 4% P. 
falciparum DNA (3D7) were amplified using either WGA or sWGA. 
Amplified samples were sequenced to determine the proportion of 
reads mapping to human or P. falciparum reference genomes
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Taken together, our data establishes 0.03% parasitae-
mia (40 parasites per 200 WBC) as the minimum thresh-
old on which sWGA technology is capable of generating 
quality sequence data with coverage suitable for most 
genetic analyses on DBS field samples (Fig.  7, vertical 
dotted line marks the 0.03% parasitaemia threshold). The 
data also show that at least 180 parasite genomes per 
sample is required for efficient sWGA processing.
Fig. 5 Assessing sWGA sensitivity and parasitaemia threshold. Clinical mock samples represent different levels of parasitaemia ranging from 0.0001 
to 1%. Data from sWGA‑processed samples were analysed to determine coverage of P. falciparum genome. a Genome coverage by samples of dif‑
ferent parasitaemia levels. b Coverage of important drug resistance loci by mock samples of different levels of parasitaemia
Fig. 6 Core genome coverage of 156 dried‑blood spot (DBS) clinical samples subjected to sWGA. a Percentage of genome positions with no cover‑
age. b Percentage of genome positions with at least 5× coverage. c Median genome coverage
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High concordance between dried blood spot samples 
and venous blood samples
In order to further evaluate sWGA efficiency and suit-
ability for genetic studies from DBS samples, a concord-
ance analysis was performed using the set of 120 field 
samples with matched pairs of VB and DBS filter papers. 
Sequence data from both VB and DBS samples were ana-
lysed in parallel and genotyped against the ~1.2 million 
high quality SNP positions previously identified in the P. 
falciparum genome [15]. Genotype calls from matching 
VB (gDNA) and DBS (sWGA) sample pairs were ana-
lysed. In the gold standard VB samples, a median of more 
than 98% (N = 1,217,003) of SNPs were called in all the 
samples (Fig.  8). Overall, 93% (N =  1,154,911) of SNPs 
were called in the DBS samples, with a slight reduction 
at a lower parasitaemia (Fig. 8). The accuracy of the SNPs 
called was investigated by performing a concordance 
analysis between SNP calls made from VB and DBS sam-
ples. Samples that had <50% of the genome covered at 5× 
(N = 7) as well as all missing calls of the remaining DBS 
samples (total samples analysed N = 113) were excluded 
from this analysis. There was high concordance between 
the SNPs called in both VB and DBS samples, with an 
average of more than 99.9% (out of 1,241,840 SNPs, SD 
10.97%) of calls being concordant (either Ref/Ref or Alt/
Alt; Table  2). Only 0.04% (out of 1,241,840 SNPs, SD 
0.08%) of calls were discordant (Ref/Alt or Alt/Ref ).
The accuracy of SNP calls from sWGA-generated data 
was further tested using allele frequency concordance 
metrics. Using the VCF files targeting the 1.2 million 
high quality-biallelic SNPs, the population-level allele 
frequencies was analysed from matching VB and DBS 
samples, and strong correlation of non-reference allele 
frequencies (NRAF) was found between VB (gDNA) 
and DBS (sWGA) samples (Fig.  9; Pearson’s correlation 
Ρ  =  0.99, p  <  0.001). For more detailed analysis, allele 
frequencies of specific mutations for key malaria drug 
resistance genes—dhfr, mdr1, crt, dhps and kelch13—
were analysed. Once again, high concordance between 
VB and DBS samples was observed (Fig.  9; Additional 
file 1: Table S1). In summary, after excluding lower qual-
ity samples with missing calls, very high concordance in 
Fig. 7 Field DBS samples with higher parasitaemia have a higher pro‑
portion of genome positions covered at depth >5×. (F(1,150) = 135.5; 
p = 0.001). The parasitaemia threshold to obtain at least 50% of the 
genome covered at 5× is 0.03% (dotted red line)
Fig. 8 Single nucleotide polymorphism (SNP) calls from matching 
venous blood samples (VB) and dried blood spots samples (DBS). The 
percentage of SNPs called in DBS samples decreases as parasitaemia 
decreases
Table 2 SNP concordance analysis of  dried blood spots 
(DBS; sWGA) and  venous blood (VB; leucodepleted 
and unamplified) samples (N = 113)
Genotype calls across ~1.2 million biallelic typable SNPs from matching VB 
and DBS (sWGA) sample pairs were analysed to obtain SNP concordance 
between the two sample processing methods. Ref, reference genotype call; Alt, 
alternative genotype call; Het, heterogeneous calls; Miss, missing calls
Ref/Ref Alt/Alt Ref/Alt Alt/Ref
Average 1,130,936.8 
(99.82%)
1,391.3 (0.12%) 288.4 (0.02%) 283.4 (0.02%)
SD 124,553.8 
(10.9%)
848.6 (0.07%) 477.8 (0.04%) 498.3 (0.04%)
Median 1,179,088 
(99.9%)
1,026 (0.08%) 0 0
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population genetic data between VB and DBS samples 
was observed.
Discussion
Using sWGA to amplify parasite DNA from dried blood 
spots has immediate and important implications for pub-
lic health. This work has comprehensively evaluated the 
potential of sWGA method. Collecting clinical malaria 
samples as DBS on filter paper is field-friendly and has 
several advantages for both patient and researcher over 
the venous blood (VB) draw methods currently used for 
parasite whole genome sequencing [23]. Finger-prick 
sampling requires less advanced training than VB draws, 
collects ~50× less blood, and is more convenient for most 
patient groups. Unlike VB draws, DBS samples also do 
not require special facilities for transportation, refrigera-
tion, and storage, since the blotted paper is stabilized by 
the membrane that preserves genetic integrity [23, 24]. 
VB sampling is thus relatively limited in geographic range, 
restricted to locations with well-established and resourced 
clinics. Sequencing from DBS samples would break this 
technical bottleneck, allowing significant expansion of 
sample collection to include very remote regions, increas-
ing sampling density and coverage [23, 24].
The data presented show that ~110  ng of genomic 
DNA can be extracted from a 20–40  µl DBS, of which 
over 98% is host material. Isolating sequenceable para-
site DNA from a DBS sample that is highly contaminated 
with host DNA has hindered applications of genetic tools 
in malaria research and control programmes. Previous 
studies have identified various methods to overcome 
the challenges of host DNA contamination in pathogen 
sequencing [4, 25]. However, most of these techniques 
require relatively large quantities of starting DNA mate-
rial that is impossible to obtain from DBS samples. The 
approach described here provides a timely solution to 
this challenge, creating opportunities for both large-scale 
field isolate sequencing studies and analysing archived 
clinical samples that would otherwise be too contami-
nated and low yield for whole genome sequencing.
To thoroughly evaluate the quality and accuracy of 
sWGA sequence data for genetic analysis of clinical 
malaria samples, 156 DBS collected from clinical malaria 
patients was sequenced and analysed using sWGA. 120 
of these had their corresponding VB counterparts col-
lected simultaneously, allowing direct comparison 
between DBS (sWGA) and VB (leucodepleted and unam-
plified) WGS data from an identical patient cohort [5, 6]. 
More than 75% of the P. falciparum genome was covered 
at ≥5× in 117 (97.5%) DBS samples for which parasitae-
mia was ≥0.03%. The sWGA-derived genome sequences 
show a less uniform coverage profile compared to data 
generated from unamplified genomic DNA (VB-derived, 
Fig.  3). This is typical of whole genome amplified data 
[12]. However, the core genome was adequately covered 
at depths suitable for most downstream analysis includ-
ing variant detection and SNP genotyping. Further opti-
mization is required to amplify and successfully genotype 
regions outside the core genome, such as telomeres and 
mitochondria.
The high concordance of SNP calls and allele frequen-
cies between the DBS and VB paired samples indicates 
that samples that were subjected to sWGA are suit-
able for population genetic studies. Significantly for the 
potential applicability of this technology to public health 
surveillance projects, important malaria drug resistance 
loci were successfully sequenced and showed very similar 
allele frequencies for both DBS and VB samples (Fig. 9; 
Additional file 1: Table S1).
Conclusion
In summary, this work shows that processing DBS sam-
ples using sWGA method produces reliable sequence 
data, provided that: the sample has ≥180 P. falciparum 
genomes (parasitaemia threshold ~0.03%, or ~40 para-
sites per 200 WBC); the threshold for library preparation 
is met (≥500 ng of DNA post-sWGA); and the sequence 
Fig. 9 Population‑level allele frequency of venous blood (VB) and 
DBS (sWGA) samples are strongly correlated. Using variant calls from 
the 1.2 million high quality‑biallelic SNP positons, non‑reference 
allele frequencies (NRAF) were compared from matching VB and 
DBS samples, and a strong correlation between the two sample sets 
was obtained. Coloured dots represent specific mutations of drug 
resistance genes. Green dots represent dhfr (N51I, C59R, S108N); blue 
dots represent mdr1 (N86Y, Y184F); red dots represent crt (M74I, N75D, 
N75K, K76T, A220S, Q271E, I356T, R371I); yellow dots represent dhps 
(S436A, G437A, K540E, A581G, A613S)
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data obtained covers at least 50% of the genome at a 
depth of 5× or more. Samples with much a lower para-
sitaemia, for example those collected from asympto-
matic patients or during the low transmission season, 
will require further optimization to improve sensitivity 
and coverage. Using sWGA technology, genomic data 
from larger sample sizes with geospatial resolution could 
provide useful information to public health bodies, for 
example through rapid detection of emerging patterns in 
parasite evolution in response to control initiatives such 
as anti-malarial drugs.
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